Detalhe da pesquisa
1.
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial.
Lancet Oncol
; 25(1): 99-107, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38043558
2.
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.
Lancet Oncol
; 25(5): 563-571, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38621400
3.
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.
Lancet Oncol
; 24(4): 323-334, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36990608
4.
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
Lancet
; 397(10276): 797-804, 2021 02 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-33581798
5.
A practical guide for the use of apalutamide for non-metastatic castration-resistant prostate cancer in Australia.
Asia Pac J Clin Oncol
; 2024 Apr 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38639402
6.
Medical management of metastatic prostate cancer.
Aust Prescr
; 41(5): 154-159, 2018 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-30410212
7.
Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP.
J Clin Oncol
; 40(8): 837-846, 2022 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34928708
8.
Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy.
Eur Urol
; 80(3): 275-279, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34030924
9.
Malignant mesothelioma of the tunica vaginalis: a atypical presentation of a rare scrotal tumour.
ANZ J Surg
; 89(12): E562-E563, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30706607
10.
New systemic treatment options for metastatic renal-cell carcinoma in the era of targeted therapies.
Asia Pac J Clin Oncol
; 6(1): 5-18, 2010 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-20398033